United Therapeutics Corporation
UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exerciseā¦ read more
Healthcare
Biotechnology
26 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$493.25
Price+1.23%
$6.00
1Y
Price
Market Cap
$22.036b
Large
Price/Earnings 3y Avg5y Avg
18.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+57.9%
EBITDA Margin+42.4%
Net Profit Margin+44.0%
Free Cash Flow Margin+57.9%
EBITDA Margin+42.4%
Net Profit Margin+44.0%
Free Cash Flow MarginRevenue
$3.128b
+8.7%
1y CAGR+17.5%
3y CAGR+16.9%
5y CAGREarnings
$1.272b
+6.4%
1y CAGR+21.1%
3y CAGR+29.0%
5y CAGREPS
$26.39
+7.1%
1y CAGR+21.2%
3y CAGR+28.2%
5y CAGRBook Value
$6.590b
$7.351b
Assets$760.900m
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
$1.122b
+3.8%
1y CAGR+20.3%
3y CAGR+25.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company